Clinical Trials Logo

Clinical Trial Summary

The overall purpose of the project is to create a scientific basis for which patients should be offered breast reduction in the public sector. More specifically , the project aims to: - To examine the evidence for current national guidelines for breast reduction. The hypothesis is that BMI, breast volume, resection weight, and mental and physical symptoms affect the outcome of breast reconstruction, both in terms of complication risks, patient satisfaction and quality of life . - To investigate which patients benefit the most from a breast reduction, in a health economic perspective. The starting point is that resources are limited and the purpose is to maximize the health effects for the patient at as low cost as possible. The hypothesis is that the health benefits, for the individual and society, are different depending on how big the breasts are and how much symptoms a patient has preoperatively. - To examine back function and objective problems in women, with both natural and augmented breasts, with different body constitutions and volumes. The hypothesis is that a certain breast volume give rise to different physical symptoms in different women, depending on their other physical factors. - To develop preferences for benign breast conditions that are treated in plastic surgery and for complications that the treatment can cause. Preferences are used to calculate QALY (quality-adjusted life years). Knowledge of preferences is essential for an analysis of healthcare needs. - To examine women's experiences of how their breast hypertrophy affects them and their expectations of a breast reduction. The hypothesis is that the experience breast hypertrophy affects patients differently, and that expectations on a breast reduction can vary between different individuals.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04889469
Study type Observational [Patient Registry]
Source Vastra Gotaland Region
Contact Emma Hansson, PhD
Phone +46313421000
Email emma.hansson.2@gu.se
Status Recruiting
Phase
Start date August 1, 2021
Completion date August 1, 2031

See also
  Status Clinical Trial Phase
Recruiting NCT04767620 - Clinical Trial of Ruxian Zengsheng No. 1 Decoction Phase 2